Interestingly, analysis of The Cancer Genome Atlas (TCGA) revealed that higher levels of mRNAs encoding the circadian clock repressor CRY2 were associated with improved survival in patients with glioma, thus supporting the hypothesis that the use of CRY-stabilizing compounds might be a promising strategy for glioblastoma therapy in humans145. The gene discussed is CRYL1; the disease is glioblastoma.